Comparison of Coronary Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Diabetes Mellitus

American Journal of Cardiology

Volumn 99, Issue 6, 2007, Pages 779-784

  Briguori, Carlo ^a,c   Condorelli, Gerolama ^b   Airoldi, Flavio ^c   Focaccio, Amelia ^a   D'Andrea, Davide ^a   Cannavale, Mario ^b   Abarghouei, Alireza Afzali ^a   Giordano, Salvatore ^a   De Vivo, Fabrizio ^a   Ricciardelli, Bruno ^a   Colombo, Antonio ^c  

^a Clinica Mediterranea   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVASCULARIZATION; RISK; SCORING SYSTEM; STROKE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33847631329     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.10.031     Document Type: Article

References (30)

1. Abizaid A., Costa M.A., Blanchard D., Albertal M., Eltchaninoff H., Guagliumi G., Geert-Jan L., Abizaid A.S., Sousa A.G., Wuelfert E., et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 25 (2004) 107-112
2. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., and Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients. Circulation 109 (2004) 2273-2278
3. Hermiller J.B., Raizner A., Cannon L., Gurbel P.A., Kutcher M.A., Wong S.C., Russell M.E., Ellis S.G., Mehran R., and Stone G.W. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
4. Dibra A., Kastrati A., Mehilli J., Pache J., Schuhlen H., von Beckerath N., Ulm K., Wessely R., Dirschinger J., and Shomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl Med J 353 (2005) 663-670
5. Sabatè M., Jimenez-Quevedo P., Angiolillo D.J., Gomez-Hospital J.A., Alfonso F., Hernandez-Antolin R., Goicolea J., Banuelos C., Escaned J., Moreno R., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
6. Briguori C., Colombo A., Airoldi F., Focaccio A., Iakovou I., Chieffo A., Michev I., Montorfano N., Bonizzoni E., Ricciarelli B., and Condorelli G. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J 150 (2005) 807-813
7. Sellke F.W., DiMaio J.M., Caplan L.R., Ferguson T.B., Gardner T.J., Hiratzka L.F., Isselbacher E.M., Lyfle B.W., Mack M.J., Murkin J.M., and Robbibs R.C. Comparing on-pump and off-pump coronary artery bypass grafting: numerous studies but few conclusions: a scientific statement from the American Heart Association council on cardiovascular surgery and anesthesia in collaboration with the interdisciplinary working group on quality of care and outcomes research. Circulation 111 (2005) 2858-2864
8. Wijeysundera D.N., Beattie W.S., Djaiani G., Rao V., Borger M.A., Karkouti K., and Cusimano R.J. Off-pump coronary artery surgery for reducing mortality and morbidity meta-analysis of randomized and observational studies. J Am Coll Cardiol 46 (2005) 872-882
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 28 suppl (2005) S37-S42
10. Marso S.P., Ellis S.G., Tuzcu M., Whitlow P.L., Franco I., Raymond R.E., and Topol E.J. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 33 (1999) 1269-1277
11. Cockcroft D.W., and Gault M.H. Prediction of creatine clearance from serum creatine. Nephron 16 (1976) 31-41
12. Sianos G., Morel M., Kappetein A.P., Morice M.C., Colombo A., Dawkins K., van den Brand M., Van Dyck N., Russel M.E., and Serruys P.W. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention 2 (2005) 219-227
13. The BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 35 (2000) 1122-1129
14. Nashef S.A., Roques F., Michel P., Gauducheau E., Lemeshow S., and Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16 (1999) 9-13
15. Abizaid A., Costa M.A., Centemero M., Abizaid A.S., Legrand V.M., Limet R.V., Schuler G., Mohr F.W., Lindeboon W., Sousa A.G., et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Circulation 104 (2001) 533-538
16. Serruys P.W., Ong A.T.L., Morice M.C., DeBruyne B., Colombo A., Macaya C., Richardt G., Fajadet J., Hamm C., Dawkins K., et al. Arterial revascularization therapies part II-sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. Eurointervention 2 (2005) 147-156
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl Med J 329 (1993) 977-986
18. Gæde P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
19. Corpus R.A., Geroge P.B., House J.A., Dixon S.R., Ajluni S.C., Devlin W.H., Timmis G.C., Balasubramaniam M., and O'Neill W.W. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43 (2004) 8-14
20. Briguori C., Condorelli G., Airoldi F., Mikhail G.W., Ricciardelli B., and Colombo A. Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients. Heart 90 (2004) 1481-1482
21. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310 (1984) 356-360
22. Mattock M.B., Morrish N.J., Viberti G., Keen H., Fitzgerald A.P., and Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41 (1992) 736-741
23. Rajala U., Pajunpaa H., Koskela P., and Keinanen-Kiukaanniemi H. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 23 (2000) 957-961
24. Kim Y.H., Hong M.K., Song J.M., Han K.H., Kang D.H., Song J.K., Kim J.J., Park S.W., and Park S.J. Diabetic retinopathy as a predictor of late clinical events following percutaneous coronary intervention. J Invasive Cardiol 10 (2002) 599-602
25. Briguori C., Condorelli G., Airoldi F., Manganelli F., Violante A., Focaccio A., Ricciarelli B., and Colombo A. Impact of microvascular complications on outcome after coronary stent implantation in patients with diabetes. J Am Coll Cardiol 45 (2005) 464-466
26. Best P.J., Lennon R., Ting H.H., Bell M.R., Rihal C.S., Holmes D.R., and Berger P.B. The impact of renal insufficiency on clinical outcome in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39 (2002) 1113-1119
27. Szczech L.A., Best P.J., Crowley E., Brooks M.M., Berger P.B., Bittner V., Gerch B.J., Jones R., Califf R.M., Ting H.H., et al. Outcome of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 105 (2002) 2253-2258
28. Serruys P.W., de Feyter P., Macaya C., Kpkott N., Pule J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., and Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
29. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Sopland I., and Fox K.A. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
30. Mehilli J., Kastrati A., Schuhlen H., Dibra A., Dotzer F., von Beckerath N., Bollwein H., Pache J., Dirschinger J., Berger P.P., and Shomig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3617-3635